What is HC Wainwright’s Estimate for EYPT Q1 Earnings?

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) – Research analysts at HC Wainwright cut their Q1 2026 earnings per share estimates for Eyepoint Pharmaceuticals in a research report issued to clients and investors on Thursday, March 5th. HC Wainwright analyst Y. Chen now expects that the company will earn ($0.76) per share for the quarter, down from their prior forecast of ($0.65). HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Eyepoint Pharmaceuticals’ current full-year earnings is ($2.13) per share. HC Wainwright also issued estimates for Eyepoint Pharmaceuticals’ Q2 2026 earnings at ($0.76) EPS, Q3 2026 earnings at ($0.70) EPS, Q4 2026 earnings at ($0.70) EPS and FY2026 earnings at ($2.93) EPS.

Several other equities analysts have also recently weighed in on EYPT. Cantor Fitzgerald raised shares of Eyepoint Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, November 25th. Chardan Capital increased their price objective on Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. TD Cowen raised Eyepoint Pharmaceuticals to a “strong-buy” rating in a research report on Friday, December 19th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $31.50.

Eyepoint Pharmaceuticals Price Performance

Shares of NASDAQ EYPT opened at $15.75 on Monday. The company has a 50-day moving average price of $15.66 and a 200-day moving average price of $14.39. The stock has a market capitalization of $1.31 billion, a P/E ratio of -4.98 and a beta of 1.72. Eyepoint Pharmaceuticals has a 1 year low of $3.91 and a 1 year high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings results on Wednesday, March 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by ($0.03). Eyepoint Pharmaceuticals had a negative net margin of 739.39% and a negative return on equity of 88.31%. The business had revenue of $0.62 million during the quarter, compared to analyst estimates of $1.01 million.

Insider Activity

In related news, insider Ramiro Ribeiro sold 42,544 shares of the stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $17.10, for a total transaction of $727,502.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.46% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. State of Alaska Department of Revenue bought a new position in Eyepoint Pharmaceuticals in the 3rd quarter valued at $50,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Eyepoint Pharmaceuticals by 51.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock worth $74,000 after buying an additional 1,358 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in shares of Eyepoint Pharmaceuticals in the 3rd quarter worth about $76,000. Tower Research Capital LLC TRC grew its position in Eyepoint Pharmaceuticals by 218.3% during the second quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock valued at $82,000 after buying an additional 5,967 shares during the period. Finally, California State Teachers Retirement System increased its holdings in Eyepoint Pharmaceuticals by 20.6% during the fourth quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock worth $85,000 after buying an additional 794 shares during the last quarter. Hedge funds and other institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.